ZFP69 zinc finger protein BGenealiases: ZKSCAN23B · ZNF643 · ZSCAN54B
Q-omics provides the consensus-scored ZFP69B profile across patient tissues and cancer cell-line models. ZFP69B expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, ZFP69B is differentially expressed in 17, with the highest sampling consensus in HNSC. Additionally, ZFP69B RNA expression shows 20,326 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight LIHC, HNSC, and UVM as cancer lineages where ZFP69B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZFP69B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZFP69B survival associations across molecular data types. ZFP69B RNA expression shows survival associations in the most cancer types (27), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZFP69B RNA expression–survival associations across cancer types. High ZFP69B expression shows unfavorable associations in LIHC, MESO, LUSC and SARC, but favorable associations in OV and GBM. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for ZFP69B RNA expression.
This table summarizes ZFP69B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 17. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for ZFP69B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZFP69B shows higher tumor expression in HNSC, KIRC, COAD, KIRP, LUSC and LUAD. The HNSC box plot shows higher ZFP69B RNA expression in tumor versus normal tissue (log2 FC = +0.863, t-test p < 0.001).
This table shows molecular features associated with ZFP69B in patient tissues and cancer cell lines. In patient samples, ZFP69B shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZFP69B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BLOOD_Leukemia.
